Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral?

Casaos J, Gorelick NL, Huq S, Choi J, Xia Y, Serra R, Felder R, Lott T, Kast RE, Suk I, Brem H, Tyler B, Skuli N.

Mol Cancer Ther. 2019 Jul;18(7):1185-1194. doi: 10.1158/1535-7163.MCT-18-0666. Review.

PMID:
31263027
2.

Gamma-Glutamyltransferase 1 Promotes Clear Cell Renal Cell Carcinoma Initiation and Progression.

Bansal A, Sanchez DJ, Nimgaonkar V, Sanchez D, Riscal R, Skuli N, Simon MC.

Mol Cancer Res. 2019 May 31. doi: 10.1158/1541-7786.MCR-18-1204. [Epub ahead of print]

PMID:
31151999
3.

Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste.

Smith SJ, Tyler BM, Gould T, Veal GJ, Gorelick N, Rowlinson J, Serra R, Ritchie A, Berry P, Otto A, Choi J, Skuli N, Estevez-Cebrero M, Shakesheff KM, Brem H, Grundy RG, Rahman R.

Clin Cancer Res. 2019 Aug 15;25(16):5094-5106. doi: 10.1158/1078-0432.CCR-18-3850. Epub 2019 May 21.

PMID:
31113843
4.

Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-MYC medulloblastoma.

Natsumeda M, Liu Y, Nakata S, Miyahara H, Hanaford A, Ahsan S, Stearns D, Skuli N, Kahlert UD, Raabe EH, Rodriguez FJ, Eberhart CG.

Neuropathology. 2019 Apr;39(2):71-77. doi: 10.1111/neup.12534. Epub 2019 Jan 10.

PMID:
30632221
5.

Augmentation of 5-Aminolevulinic Acid Treatment of Glioblastoma by Adding Ciprofloxacin, Deferiprone, 5-Fluorouracil and Febuxostat: The CAALA Regimen.

Kast RE, Skuli N, Sardi I, Capanni F, Hessling M, Frosina G, Kast AP, Karpel-Massler G, Halatsch ME.

Brain Sci. 2018 Nov 22;8(12). pii: E203. doi: 10.3390/brainsci8120203.

6.

Myeloid Cell Hypoxia-Inducible Factors Promote Resolution of Inflammation in Experimental Colitis.

Lin N, Shay JES, Xie H, Lee DSM, Skuli N, Tang Q, Zhou Z, Azzam A, Meng H, Wang H, FitzGerald GA, Simon MC.

Front Immunol. 2018 Nov 5;9:2565. doi: 10.3389/fimmu.2018.02565. eCollection 2018.

7.

PPARγ is dispensable for clear cell renal cell carcinoma progression.

Sanchez DJ, Steger DJ, Skuli N, Bansal A, Simon MC.

Mol Metab. 2018 Aug;14:139-149. doi: 10.1016/j.molmet.2018.05.013. Epub 2018 May 21.

8.

Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors.

Casaos J, Huq S, Lott T, Felder R, Choi J, Gorelick N, Peters M, Xia Y, Maxwell R, Zhao T, Ji C, Simon T, Sesen J, Scotland SJ, Kast RE, Rubens J, Raabe E, Eberhart CG, Jackson EM, Brem H, Tyler B, Skuli N.

Oncotarget. 2018 Jan 3;9(8):8054-8067. doi: 10.18632/oncotarget.23883. eCollection 2018 Jan 30.

9.

Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

Malric L, Monferran S, Gilhodes J, Boyrie S, Dahan P, Skuli N, Sesen J, Filleron T, Kowalski-Chauvel A, Cohen-Jonathan Moyal E, Toulas C, Lemarié A.

Oncotarget. 2017 Aug 21;8(49):86947-86968. doi: 10.18632/oncotarget.20372. eCollection 2017 Oct 17. Review.

10.

HIF-1α- Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy.

Mangraviti A, Raghavan T, Volpin F, Skuli N, Gullotti D, Zhou J, Asnaghi L, Sankey E, Liu A, Wang Y, Lee DH, Gorelick N, Serra R, Peters M, Schriefer D, Delaspre F, Rodriguez FJ, Eberhart CG, Brem H, Olivi A, Tyler B.

Sci Rep. 2017 Nov 2;7(1):14978. doi: 10.1038/s41598-017-14990-w.

11.

Blocking epithelial-to-mesenchymal transition in glioblastoma with a sextet of repurposed drugs: the EIS regimen.

Kast RE, Skuli N, Karpel-Massler G, Frosina G, Ryken T, Halatsch ME.

Oncotarget. 2017 Jun 1;8(37):60727-60749. doi: 10.18632/oncotarget.18337. eCollection 2017 Sep 22.

12.

The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.

Kast RE, Skuli N, Cos S, Karpel-Massler G, Shiozawa Y, Goshen R, Halatsch ME.

Breast Cancer (Dove Med Press). 2017 Jul 11;9:495-514. doi: 10.2147/BCTT.S139963. eCollection 2017.

13.

Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, Frikeche J, Lott T, Felder R, Scotland SJ, Eisinger-Mathason TSK, Brem H, Tyler B, Skuli N.

Oncogene. 2017 May 25;36(21):3037-3047. doi: 10.1038/onc.2016.457. Epub 2016 Dec 12.

PMID:
27941882
14.

The Bad, the Good and eIF3e/INT6.

Sesen J, Casaos J, Scotland SJ, Seva C, Eisinger-Mathason TS, Skuli N.

Front Biosci (Landmark Ed). 2017 Jan 1;22:1-20. Review.

PMID:
27814599
15.

A novel cytoprotective function for the DNA repair protein Ku in regulating p53 mRNA translation and function.

Lamaa A, Le Bras M, Skuli N, Britton S, Frit P, Calsou P, Prats H, Cammas A, Millevoi S.

EMBO Rep. 2016 Apr;17(4):508-18. doi: 10.15252/embr.201541181. Epub 2016 Mar 10.

16.

HIF modulation of Wnt signaling regulates skeletal myogenesis in vivo.

Majmundar AJ, Lee DS, Skuli N, Mesquita RC, Kim MN, Yodh AG, Nguyen-McCarty M, Li B, Simon MC.

Development. 2015 Jul 15;142(14):2405-12. doi: 10.1242/dev.123026. Epub 2015 Jul 7.

17.

Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis.

Eisinger-Mathason TS, Mucaj V, Biju KM, Nakazawa MS, Gohil M, Cash TP, Yoon SS, Skuli N, Park KM, Gerecht S, Simon MC.

Proc Natl Acad Sci U S A. 2015 Jun 30;112(26):E3402-11. doi: 10.1073/pnas.1420005112. Epub 2015 Jun 15.

18.

Feedback circuitry between miR-218 repression and RTK activation in glioblastoma.

Mathew LK, Huangyang P, Mucaj V, Lee SS, Skuli N, Eisinger-Mathason TS, Biju K, Li B, Venneti S, Lal P, Lathia JD, Rich JN, Keith B, Simon MC.

Sci Signal. 2015 May 5;8(375):ra42. doi: 10.1126/scisignal.2005978.

19.

Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.

Sesen J, Dahan P, Scotland SJ, Saland E, Dang VT, Lemarié A, Tyler BM, Brem H, Toulas C, Cohen-Jonathan Moyal E, Sarry JE, Skuli N.

PLoS One. 2015 Apr 13;10(4):e0123721. doi: 10.1371/journal.pone.0123721. eCollection 2015.

20.

The aryl hydrocarbon receptor nuclear translocator is an essential regulator of murine hematopoietic stem cell viability.

Krock BL, Eisinger-Mathason TS, Giannoukos DN, Shay JE, Gohil M, Lee DS, Nakazawa MS, Sesen J, Skuli N, Simon MC.

Blood. 2015 May 21;125(21):3263-72. doi: 10.1182/blood-2014-10-607267. Epub 2015 Apr 8.

21.

MicroRNA-124 expression counteracts pro-survival stress responses in glioblastoma.

Mucaj V, Lee SS, Skuli N, Giannoukos DN, Qiu B, Eisinger-Mathason TS, Nakazawa MS, Shay JE, Gopal PP, Venneti S, Lal P, Minn AJ, Simon MC, Mathew LK.

Oncogene. 2015 Apr 23;34(17):2204-14. doi: 10.1038/onc.2014.168. Epub 2014 Jun 23.

22.

Preclinical evidence that SSR128129E--a novel small-molecule multi-fibroblast growth factor receptor blocker--radiosensitises human glioblastoma.

Ader I, Delmas C, Skuli N, Bonnet J, Schaeffer P, Bono F, Cohen-Jonathan-Moyal E, Toulas C.

Eur J Cancer. 2014 Sep;50(13):2351-9. doi: 10.1016/j.ejca.2014.05.012. Epub 2014 Jun 18.

PMID:
24953334
23.

Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.

Furcht CM, Buonato JM, Skuli N, Mathew LK, Muñoz Rojas AR, Simon MC, Lazzara MJ.

J Cell Sci. 2014 Aug 15;127(Pt 16):3555-67. doi: 10.1242/jcs.150862. Epub 2014 Jun 20.

24.

Int6/eIF3e is essential for proliferation and survival of human glioblastoma cells.

Sesen J, Cammas A, Scotland SJ, Elefterion B, Lemarié A, Millevoi S, Mathew LK, Seva C, Toulas C, Moyal EC, Skuli N.

Int J Mol Sci. 2014 Jan 29;15(2):2172-90. doi: 10.3390/ijms15022172.

25.

Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer.

Shay JE, Imtiyaz HZ, Sivanand S, Durham AC, Skuli N, Hsu S, Mucaj V, Eisinger-Mathason TS, Krock BL, Giannoukos DN, Simon MC.

Carcinogenesis. 2014 May;35(5):1067-77. doi: 10.1093/carcin/bgu004. Epub 2014 Jan 9.

26.

miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.

Mathew LK, Skuli N, Mucaj V, Lee SS, Zinn PO, Sathyan P, Imtiyaz HZ, Zhang Z, Davuluri RV, Rao S, Venneti S, Lal P, Lathia JD, Rich JN, Keith B, Minn AJ, Simon MC.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):291-6. doi: 10.1073/pnas.1314341111. Epub 2013 Dec 24.

27.

Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.

Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC.

Cancer Discov. 2014 Jan;4(1):53-60. doi: 10.1158/2159-8290.CD-13-0291. Epub 2013 Nov 4.

28.

Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis.

Eisinger-Mathason TS, Zhang M, Qiu Q, Skuli N, Nakazawa MS, Karakasheva T, Mucaj V, Shay JE, Stangenberg L, Sadri N, Puré E, Yoon SS, Kirsch DG, Simon MC.

Cancer Discov. 2013 Oct;3(10):1190-205. doi: 10.1158/2159-8290.CD-13-0118. Epub 2013 Aug 1.

29.

Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways.

Kim JS, Sklarz T, Banks LB, Gohil M, Waickman AT, Skuli N, Krock BL, Luo CT, Hu W, Pollizzi KN, Li MO, Rathmell JC, Birnbaum MJ, Powell JD, Jordan MS, Koretzky GA.

Nat Immunol. 2013 Jun;14(6):611-8. doi: 10.1038/ni.2607. Epub 2013 May 5. Retraction in: Nat Immunol. 2014 Oct;15(10):996.

30.

Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells.

Scotland S, Saland E, Skuli N, de Toni F, Boutzen H, Micklow E, Sénégas I, Peyraud R, Peyriga L, Théodoro F, Dumon E, Martineau Y, Danet-Desnoyers G, Bono F, Rocher C, Levade T, Manenti S, Junot C, Portais JC, Alet N, Récher C, Selak MA, Carroll M, Sarry JE.

Leukemia. 2013 Nov;27(11):2129-38. doi: 10.1038/leu.2013.107. Epub 2013 Apr 9.

PMID:
23568147
31.

ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation.

Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, Mayes PA, Wise DR, Thompson CB, Maris JM, Hogarty MD, Simon MC.

Cancer Cell. 2012 Nov 13;22(5):631-44. doi: 10.1016/j.ccr.2012.09.021.

32.

Dynamic regulation of the cerebral cavernous malformation pathway controls vascular stability and growth.

Zheng X, Xu C, Smith AO, Stratman AN, Zou Z, Kleaveland B, Yuan L, Didiku C, Sen A, Liu X, Skuli N, Zaslavsky A, Chen M, Cheng L, Davis GE, Kahn ML.

Dev Cell. 2012 Aug 14;23(2):342-55. doi: 10.1016/j.devcel.2012.06.004.

33.

Hypoxia-induced angiogenesis: good and evil.

Krock BL, Skuli N, Simon MC.

Genes Cancer. 2011 Dec;2(12):1117-33. doi: 10.1177/1947601911423654.

34.

Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes.

Skuli N, Majmundar AJ, Krock BL, Mesquita RC, Mathew LK, Quinn ZL, Runge A, Liu L, Kim MN, Liang J, Schenkel S, Yodh AG, Keith B, Simon MC.

J Clin Invest. 2012 Apr;122(4):1427-43. doi: 10.1172/JCI57322. Epub 2012 Mar 19.

35.

O(2) regulates skeletal muscle progenitor differentiation through phosphatidylinositol 3-kinase/AKT signaling.

Majmundar AJ, Skuli N, Mesquita RC, Kim MN, Yodh AG, Nguyen-McCarty M, Simon MC.

Mol Cell Biol. 2012 Jan;32(1):36-49. doi: 10.1128/MCB.05857-11. Epub 2011 Oct 17.

36.

Hemodynamic and metabolic diffuse optical monitoring in a mouse model of hindlimb ischemia.

Mesquita RC, Skuli N, Kim MN, Liang J, Schenkel S, Majmundar AJ, Simon MC, Yodh AG.

Biomed Opt Express. 2010 Oct 15;1(4):1173-1187.

37.

The tumor suppressor LKB1 emerges as a critical factor in hematopoietic stem cell biology.

Krock B, Skuli N, Simon MC.

Cell Metab. 2011 Jan 5;13(1):8-10. doi: 10.1016/j.cmet.2010.12.015.

38.

Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha.

Qing G, Skuli N, Mayes PA, Pawel B, Martinez D, Maris JM, Simon MC.

Cancer Res. 2010 Dec 15;70(24):10351-61. doi: 10.1158/0008-5472.CAN-10-0740. Epub 2010 Oct 20.

39.

HIF-1alpha versus HIF-2alpha in endothelial cells and vascular functions: is there a master in angiogenesis regulation?

Skuli N, Simon MC.

Cell Cycle. 2009 Oct 15;8(20):3252-3. Epub 2009 Oct 25. No abstract available.

40.

Endothelial deletion of hypoxia-inducible factor-2alpha (HIF-2alpha) alters vascular function and tumor angiogenesis.

Skuli N, Liu L, Runge A, Wang T, Yuan L, Patel S, Iruela-Arispe L, Simon MC, Keith B.

Blood. 2009 Jul 9;114(2):469-77. doi: 10.1182/blood-2008-12-193581. Epub 2009 May 13.

41.

Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.

Skuli N, Monferran S, Delmas C, Favre G, Bonnet J, Toulas C, Cohen-Jonathan Moyal E.

Cancer Res. 2009 Apr 15;69(8):3308-16. doi: 10.1158/0008-5472.CAN-08-2158. Epub 2009 Apr 7.

42.

Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.

Monferran S, Skuli N, Delmas C, Favre G, Bonnet J, Cohen-Jonathan-Moyal E, Toulas C.

Int J Cancer. 2008 Jul 15;123(2):357-364. doi: 10.1002/ijc.23498.

43.

Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells.

Skuli N, Monferran S, Delmas C, Lajoie-Mazenc I, Favre G, Toulas C, Cohen-Jonathan-Moyal E.

Cancer Res. 2006 Jan 1;66(1):482-9.

Supplemental Content

Support Center